Abstract Number: 1036 • 2018 ACR/ARHP Annual Meeting
Effects of Three Potential Anabolic Disease-Modifying Osteoarthritis Drugs – Sprifermin, Insulin-like Growth Factor 1 and Bone Morphogenetic Protein 7 – on Matrix Production and the Phenotype of Articular Chondrocytes
Background/Purpose: Disease-modifying osteoarthritis drugs with an anabolic mode of action should stimulate the growth of new hyaline cartilage. For instance, recombinant human fibroblast growth factor…Abstract Number: 2142 • 2018 ACR/ARHP Annual Meeting
Exposure to Disease Modifying Antirheumatic Drugs during Pregnancy in Women with Inflammatory Arthritis and the Risk of Serious Maternal Infection: A Population-Based Cohort Study
Background/Purpose: Infection risk is one of the concerns regarding therapy with conventional disease modifying antirheumatic drugs (csDMARDs) and to our knowledge no research has examined…Abstract Number: 2368 • 2018 ACR/ARHP Annual Meeting
Patient Preferences for Disease Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review
Background/Purpose: Treatment choices in rheumatoid arthritis (RA) involve trade-offs in risks, benefits and other considerations such as dosing. Understanding patient preferences for these trade-offs is…Abstract Number: 2861 • 2018 ACR/ARHP Annual Meeting
Clinical Laboratory Telephone Communication Outreach to Rheumatology Patients Improves Guideline-Concordant Timeliness of Monitoring of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Background/Purpose: The American College of Rheumatology has published guidelines for laboratory monitoring of conventional DMARDs (cDMARDs). At Kaiser Permanente Colorado (KPCO), although most patients eventually…Abstract Number: 548 • 2018 ACR/ARHP Annual Meeting
Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Background/Purpose: Monotherapy with etanercept (ETN) may be a viable therapeutic option for maintenance of patients with rheumatoid arthritis (RA) who prefer to eliminate potential burdens…Abstract Number: 979 • 2018 ACR/ARHP Annual Meeting
Stopping Medicines for Inactive Juvenile Idiopathic Arthritis: What Do Patients and Families Consider?
Background/Purpose: Prior research has focused on factors important to clinicians in decisions about withdrawing JIA therapy. Based on recent interviews with patients and caregivers about…Abstract Number: 122 • 2017 ACR/ARHP Annual Meeting
Poor Prognostic Factors at the Start of Methotrexate Therapy Are Not Associated with Worse Treatment Response: Results from the Rheumatoid Arthritis Medication Study
Background/Purpose: As anti-citrullinated protein antibody positivity (+), RF+ and erosions are independently associated with poor outcomes in patients (pts) with RA, clinicians may use these…Abstract Number: 448 • 2017 ACR/ARHP Annual Meeting
Predicting Remission at 6 Months in Early Rheumatoid Arthritis Treated with Conventional Synthetic Dmards
Background/Purpose: Initial treatment of RA with triple csDMARD therapy can achieve remission in a proportion of patients. Others respond poorly yet must wait at least…Abstract Number: 538 • 2017 ACR/ARHP Annual Meeting
Severe Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. It is…Abstract Number: 1313 • 2017 ACR/ARHP Annual Meeting
Oral Corticosteroid Use during Pregnancy and Risk of Preterm Birth in Women with Rheumatoid Arthritis
Background/Purpose: There are limited data regarding gestational timing of oral corticosteroid (OCS) use during pregnancy and risk of preterm birth. The objective was to compare…Abstract Number: 1385 • 2017 ACR/ARHP Annual Meeting
Decisional Conflict in Doctor – Patient Discussions about Disease Modifying Anti-Rheumatic Drugs
Background/Purpose: There are few published studies describing patient-physician discussions about initiating new rheumatoid arthritis (RA) medications in real world settings. The purpose of this study…Abstract Number: 1443 • 2017 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…Abstract Number: 1469 • 2017 ACR/ARHP Annual Meeting
Treatment Paradigms in Real-World Practice: Biologic Agent Use Prior to and after Discontinuation of Abatacept
Background/Purpose: ACTION is a 2-year, observational study of patients (pts) with moderate-to-severe RA who initiated IV abatacept in Canada and Europe (NCT02109666). The objective was…Abstract Number: 2275 • 2017 ACR/ARHP Annual Meeting
Factors Related to Sustained Discontinuation of Medications for Well-Controlled JIA in the Childhood Arthritis & Rheumatology Research Alliance Registry
Background/Purpose: Stopping medications is a priority for many patients with well-controlled JIA, but few factors predict favorable outcomes after discontinuation. We examined factors associated with…Abstract Number: 2782 • 2017 ACR/ARHP Annual Meeting
Patient Beliefs and Preference to Initiate a Proposed Medication in Rheumatoid Arthritis
Background/Purpose : Normative economic theory assumes that people making decisions have complete information of the options, rationally weigh the opportunity costs, expected outcomes and optimize…
ACR Meeting Abstracts